PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Issues $150.0 Million of 2.75% Convertible Senior Notes Due 2021
PDL BioPharma to Present at the 28th Annual Piper Jaffray Healthcare Conference
PDL BioPharma Prices Public Offering of $150.0 Million of 2.75% Convertible Senior Notes Due 2021
PDL BioPharma Announces Proposed $150 Million Public Offering of New Convertible Senior Notes Due 2021
PDL BioPharma Announces Third Quarter 2016 Financial Results